Sunday, June 1, 2025
Your Health 247
Advertisement
  • Home
  • Health
  • Fitness
  • Diseases
  • Nutrition
  • Weight Loss
  • Meditation
  • Wellbeing Tips
  • Suppliments
  • Yoga
No Result
View All Result
  • Home
  • Health
  • Fitness
  • Diseases
  • Nutrition
  • Weight Loss
  • Meditation
  • Wellbeing Tips
  • Suppliments
  • Yoga
No Result
View All Result
Your Health 247
No Result
View All Result
Home Health

Novo Nordisk, Zepbound, Orexo, Arrakis

Your Health 247 by Your Health 247
December 4, 2024
in Health
0 0
0
Novo Nordisk, Zepbound, Orexo, Arrakis
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter



Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hullo. Lots today on GLP-1s: First we see tirzepatide outperforming semaglutide in a head-to-head study in obesity. Also, compounding pharmacies fire back at Novo Nordisk for its assertion that GLP-1 drugs are too difficult to compound. Also, a Michael Gilman company pivots and more.

Zepbound beat Wegovy head to head for weight loss

Eli Lilly’s drug Zepbound resulted in weight loss that was 47% greater than the weight loss achieved with Wegovy, the rival medicine made by Novo Nordisk, according to a new head-to-head study out this morning. The news likely will not be entirely surprising to the physicians and scientists who closely watch this space: Similar results have been seen when the same drugs — that is, tirzepatide and semaglutide, respectively — are used to treat diabetes.

In the 751-volunteer trial, volunteers receiving Zepbound lost 20.2% of their body weight on average after 72 weeks, compared to 13.7% in those treated with Wegovy. This translated into a 50.3 lbs in the tirzepatide group and 33.1 lbs in the semaglutide group.

Read more.

Arrakis pivots away from cancer

Arrakis Therapeutics, led by biotech veteran Michael Gilman, is transitioning from a focus on cancer to myotonic dystrophy, citing the many challenges it’s faced in developing RNA-intercepting drugs. Arrakis initially tried to target the elusive Myc oncogene, but faced a number of setbacks and technological “cul-de-sacs,” STAT’s Jason Mast writes, delaying progress and prompting layoffs.

Although data were promising and showed that the Arrakis drug could halve Myc expression in mouse tumors, the company’s shelving the program given investor disinterest and the long timeline needed to develop oncology drugs. With myotonic dystrophy, there’s the hope of quicker clinical results and the potential to outperform existing treatments. Arrakis plans on beginning human trials in 2026, and having data in hand before funding is set to run out in 2027.

Read more.

Compounding pharmacies rebut Novo’s FDA petition

Back in October, Novo Nordisk petitioned the FDA to bar compounding pharmacies from copying its weight loss drug semaglutide, citing safety concerns about the purity of these facsimiles. There have been ongoing shortages of GLP-1 drugs, and compounding pharmacies have stepped in to fill in supply gaps; to the chagrin of branded drugmakers, they have ended up with a pronounced market share of their own.

Now, in a lengthy letter, the Alliance for Pharmacy Compounding has now rebutted Novo’s argument, saying that the company’s assertion that compounded versions of the drugs are inferior is “unpersuasive.” The letter says that Novo “disingenuously asserts” that compounded versions are unsafe and unreliable, highlighting patient satisfaction with the products — and says that these drugs have no place on the FDA’s “Demonstrably Difficult to Compound” lists.

Orexo is divesting Deprexis, as it won’t sell

Sweden-based drugmaker Orexo is giving up on Deprexis, its digital app meant to treat depression. The company’s tried to sell it for years to no avail, and now will no longer license the product. Although it’s been a struggle to secure reimbursement for digital therapeutics in the U.S., Orexo’s timing is a bit surprising: Just a few weeks ago, Medicare created a pathway to help pay for some digital mental health treatment, STAT’s Mario Aguilar writes.

“If you look at our balance sheet and our financial situation right now, you will understand that there is a need for us to focus,” CEO Nikolaj Sørenson told STAT. Though the company was one plushly funded, its stock has dropped more than 80% since its peak in 2020. Most of Orexo’s revenue comes from Zubsolv, a drug used to treat opioid addiction.

Read more.

More reads

Coherus, sharpening immuno-oncology franchise, sells another biosimilar for over $500 million, BioPharma Dive
RFK Jr. was paid six figures by his vaccine-challenging group before presidential run, STAT
Ipsen enlists MAITs to take down solid tumors, betting $610M on Biomunex’s novel T-cell engagers, FierceBiotech
Biogen expects steady growth for Alzheimer’s drug Leqembi in near term, Reuters



Source link

Tags: ArrakisNordiskNovoOrexoZepbound
Previous Post

Australia’s net migration still 82,000 people short of pre-pandemic levels, study finds | Australian immigration and asylum

Next Post

New research shows that the heart has a mini-brain—its own nervous system that controls the heartbeat

Next Post
New research shows that the heart has a mini-brain—its own nervous system that controls the heartbeat

New research shows that the heart has a mini-brain—its own nervous system that controls the heartbeat

Facebook Twitter Instagram Youtube RSS
Your Health 247

Discover the latest in health and fitness with Your Health 247. Get expert advice, workout routines, healthy recipes, and mental wellness tips to lead a healthier, happier life. Stay informed and empowered with us!

CATEGORIES

  • Diseases
  • Fitness
  • Health
  • Meditation
  • Nutrition
  • Suppliments
  • Weight Loss
  • Wellbeing Tips
  • Yoga
No Result
View All Result

SITEMAP

  • About Us
  • Advertise with Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Health
  • Fitness
  • Diseases
  • Nutrition
  • Weight Loss
  • Meditation
  • Wellbeing Tips
  • Suppliments
  • Yoga

Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In